Quince Therapeutics Announces 1-for-10 Reverse Stock Split Effective April 10, 2026

Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the implementation of a 1-for-10 reverse stock split of its common stock. The company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on April 9, 2026, which is scheduled to become effective at 11:59 p.m. Eastern Time on April 10, 2026. Shares of the company’s common stock are expected to begin trading on a split-adjusted basis on the Nasdaq Global Select Market at the market open on April 13, 2026, under the existing ticker symbol 'QNCX' but with a new CUSIP number. As a result of the split, every ten shares of issued and outstanding common stock will be automatically combined into one share. The total number of issued and outstanding shares will be reduced to approximately 16,300,795. No fractional shares will be issued; instead, stockholders will receive cash in lieu of fractional shares based on the closing price on the filing date. All outstanding stock options and warrants will be proportionally adjusted.